What type of study is this?

This is a Meta-Analysis study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

This research focuses on the effects of Iberdomide combined with daratumumab and dexamethasone on MRD negativity in transplant-ineligible patients with newly diagnosed multiple myeloma.

December 8, 2025Blood

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

View Full Paper

Ask AI

Bookmark

Authors

SSSanhita Sengupta PMPaulo Maciag AGAnita K. Gandhi

Discussion

Member takes

Overview

Longitudinal analysis shows high MRD negativity rates in transplant-ineligible multiple myeloma patients treated with IberDd, indicating robust antitumor activity.

Key Points

This research focuses on the effects of Iberdomide combined with daratumumab and dexamethasone on MRD negativity in transplant-ineligible patients with newly diagnosed multiple myeloma.
Eligible patients with newly diagnosed multiple myeloma received oral Iberdomide along with daratumumab and dexamethasone.
Patients underwent peripheral blood immunophenotyping via flow cytometry and serum free light chain assays.
MRD evaluation was assessed through the EuroFlow assay and data analyzed comparing MRD negativity and immune changes.
44% of patients achieved minimal residual disease-negative complete response at any time.
Among those achieving MRD-negative complete response, 63.6% maintained this status at 12 months.
Sustained MRD-negative complete response was seen in 48.5% of patients at 6 months post-response.

Cite This Study

Sengupta et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0cc https://doi.org/10.1182/blood-2025-2255

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

View Full Paper

Ask AI

Bookmark

Authors

SSSanhita Sengupta PMPaulo Maciag AGAnita K. Gandhi

Discussion

Member takes

Overview

Longitudinal analysis shows high MRD negativity rates in transplant-ineligible multiple myeloma patients treated with IberDd, indicating robust antitumor activity.

Key Points

This research focuses on the effects of Iberdomide combined with daratumumab and dexamethasone on MRD negativity in transplant-ineligible patients with newly diagnosed multiple myeloma.
Eligible patients with newly diagnosed multiple myeloma received oral Iberdomide along with daratumumab and dexamethasone.
Patients underwent peripheral blood immunophenotyping via flow cytometry and serum free light chain assays.
MRD evaluation was assessed through the EuroFlow assay and data analyzed comparing MRD negativity and immune changes.
44% of patients achieved minimal residual disease-negative complete response at any time.
Among those achieving MRD-negative complete response, 63.6% maintained this status at 12 months.
Sustained MRD-negative complete response was seen in 48.5% of patients at 6 months post-response.

Cite This Study

Sengupta et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0cc https://doi.org/10.1182/blood-2025-2255

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark